You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Circulating Diagnostic Markers of Infectious Disease

    SBC: PATHOVACS INCORPORATED            Topic: CBD18A001

    Assays for accurate diagnosis of early stages of infection with biothreat agents, on the day of infection or within a few days of infection, will find wide use in both civilian and military applications These diagnostic assays, which are anticipated to be highly specific and sensitive, will add to the repertoire of tools of hospitals and clinics that serve our armed forces personnel deployed on th ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  2. Circulating Diagnostic Markers of Infectious Disease

    SBC: PATHOVACS INCORPORATED            Topic: CBD18A001

    The focus of this STTR phase I component is on proof-of-concept studies demonstrating applicability of technical approaches for identificationof circulatory diagnostic markers for infectious disease. Therefore, the primary objective of this project is to determine feasibility of one suchtechnical approach called Proteomics-based Expression Library Screening (PELS), for identification of pathogen-d ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  3. Improved Venezuelan equine encephalitis virus vaccines

    SBC: BIOPROTECTION SYSTEMS CORP.            Topic: CBD08105

    We hypothesize that the application of the broad-spectrum immune-stimulatory and -modulatory HyperAcute alphaGal Adjuvant Technology will enhance the potency and effectiveness of VEEV vaccine candidates. To complement the exciting preclinical and clinical results obtained with alphaGal-modified anti-cancer vaccines, and preclinical studies with both Ebolavirus and Influenza virus, we will apply th ...

    SBIR Phase II 2009 Department of DefenseOffice for Chemical and Biological Defense
  4. Multiple Indication Adjuvants

    SBC: BIOPROTECTION SYSTEMS CORP.            Topic: CBD08105

    The objective of this study is to demonstrate the efficacy and broad applicability of the human immune-modulating alphaGal Adjuvant Technology for antiviral vaccine development. We will use viral vaccine candidates for the select Category A viral pathogens Zaire ebolavirus (ZEBOV, filovirus), Rift Valley fever virus (RVFV, bunyavirus), and Lassa virus (LV, arenavirus), to evaluate the adjuvant pot ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government